81. Meijer WEE, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164: 2367-70.
82. Van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: Retrospective cohort study. BMJ 2001; 22: 323: 655-8.
83. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute myocardial infarction or unstable angina. JAMA 2002; 288: 701-9.
84. Lara et al, Increased cholesterol levels during paroxetine administration in healthy men. J Clin Psychiatry 2003; 64: 1455-9.
85. Dannon PN, Iancu I, Cohen A, Lowengrub K, Grunhaus L, Kotler M. Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry 2004; 11: 4: 16.
86. Brunckhorst CB, Holzmeister J, Scharf C, Binggeli C, Duru F. Stress, depression and cardiac arrhythmias. Ther Umsch 2003; 60: 673-81.
87. Ehlert U, Gaab J, Heinrichs M. Psychoneuroendocrinological contributions to the etiology of depression, posttraumatic stress disorder, and stress-related bodily disorders: the role of the hypothalamus-pituitaryadrenal axis. Biol Psychol 2001; 57:141-52.
88. Gold PW, Licinio J, Wong ML, Chrousos GP. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann N Y Acad Sci 1995; 771: 716-29.
89. Kasckow JW, Baker D, Geracioti TD, Jr. Corticotropin-releasing hormone in depression and post-traumatic stress disorder. Peptides 2001; 22: 845-51.
90. Sachar EJ, Hellman L, Fukushima DK, Gallagher TF. Cortisol production in depressive illness: a clinical and biochemical clarification. Arch Gen Psychiatry 1970; 23: 289–98.
91. Kathol RG, Jaeckle RS, Lopez JF, Meller WH. Consistent reduction of ACTH responses to stimulation with CRH, vasopressin, and hypoglycaemia in patients with major depression. Br J Psychiatry 1989; 155: 468-78.
92. Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996; 153: 1313-7.
93. Appels A, Bar FW, Bar J, Bruggeman C, de Baets M. Inflammation, depressive symptomatology, and coronary artery disease. Psychosom Med 2000; 62: 601-5.
94. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 11-38.
95. McCaffery JM, Frasure-Smith N, Dubé M-P, Théroux P, Rouleau GA, Duan QL, et al. Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom Med 2006; 68: 187-200.
96. Fumeron F, Betoulle D, Nicaud V, Evans A, Kee F, Ruidavets JB, et al. Serotonin transporter gene polymorphism and myocardial infarction: Etude CasTemoins de l’Infarctus du Myocarde (ECTIM). Circulation 2002; 105: 2943-5.
97. Baghai TC, Binder EB, Schule C, Salyakina D, Eser D, Lucae S, et al. Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol Psychiatry 2006; 11: 1003-15.
98. Gidron Y, Gilutz H, Berger R, Huleihel M. Molecular and cellular interface between behavior and acute coronary syndromes. Cardiovasc Res 2002; 56: 15-21.
99. Lespérance F, Frasure-Smith N, Koszycki D, Laliberte MA, van Zyl LT, Baker B, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease. The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial. JAMA 2007; 297: 367- 79.
100. Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev 2005; 24: 205-14.
101. Van den Brink RH, van Melle JP, Honig A, Schene AH, Crijns HJ, Lambert FP, et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). Am Heart J 2002; 144: 219-25. 54.
102. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL,van Zyl LT, et al; Sertraline AntiDepressant Heart Attack Randomized Trial Study Group. Platelet/endothelial biomarkers in depressed patients treated with theselective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003; 108: 939-44.
103. Ziegelstein RC, Meuchel J, Kim TJ, Latif M, Alvarez W, Dasgupta N, et al.Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. Am J Med 2007; 120: 525-30.
104. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003; 108: 32-6.
105. Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: Sertraline Antidepressant Heart Attack Randomized Trial. JAMA 2002; 288: 701-9.
106. Writing Committee for the ENRICHD Investigators. The effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003; 289: 3106-16.
107. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 1840-7.
108. Koenig HG, George LK, Peterson BL, Pieper CF. Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Am J Psychiatry 1997; 154: 1376-83
109. REVISIÓN REV URUG CARDIOL 2007; 22 Depresión y enfermedad cardiovascular DR. CARLOS E. ROMERO
110. Ai AL, Peterson C, Dunkle RE, Saunders DG, Bolling SF, Buchtel HA. How gender affects psychological adjustment one year after coronary artery bypass graft surgery. Women Health 1997;26:45–65.
111. 54. Con AH, Linden W, Thompson JM, Ignaszewski A. The psychology of men and women recovering from coronary artery bypass surgery. J Cardpulm Rehabil 1999;19:152–61.
112. Czajkowski SM, Terrin M, Lindquist R, Hoogwerf B, Dupuis G, Shumaker SA, Gray JR, Herd JA, Treat-Jacobson D, Zyzanski S, Knatterud GL. Comparison of preoperative characteristics of men and women undergoing coronary artery bypass grafting (the Post Coronary Artery Bypass Graft [CABG] Biobehavioral Study). Am J Cardiol 1997;79: 1017–24.
113. Eaker ED. Psychosocial risk factors for coronary heart disease in women. Cardiol Clinics 1998;16:103–11.
114. Ayanian JZ, Guadagnoli E, Cleary PD. Physical and psychosocial functioning of women and men after coronary artery bypass surgery. JAMA 1995;274:1767–70.
115. O’Connor NJ, Morton JR, Birkmeyer JD, Olmstead EM, O’Connor GT. Effect of coronary artery diameter in patients undergoing coronary bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 1996;93:652–5.
116. Murberg TA, Bru E, Svebak S, Tveteras R, Aarsland T. Depressed mood and subjective health symptoms as predictors of mortality in patients with congestive heart failure: a two-years follow-up study. Int J Psychiatry Med 1999;29:311–26.
117. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160:2101–7.
118. Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol 1995;14:88–90.
119. Blumenthal JA, Williams RS, Wallace AG, Williams RB, Jr, Needles TL. Physiological and psychological variables predict compliance to prescribed exercise therapy in patients recovering from myocardial infarction. Psychosom Med 1982;44:519–27.
120. Carney RM, Freedland KE, Eisen SA, Rich MW, Skala JA, Jaffe AS. Adherence to a prophylactic medication regimen in patients with symptomatic versus asymptomatic ischemic heart disease. Behav Med 1998; 24:35–9.